WHO calls for more studies into H1N1 vaccine
Source: Agencies |
February 9, 2011, Wednesday
|
Print Edition
Print Edition
THE World Health Organization said yesterday more investigation was needed into the possible risk of narcolepsy, a rare sleeping disorder, from GlaxoSmithKline's Pandemrix H1N1 flu vaccine.
A WHO advisory panel made the decision after a Finnish study published last week suggested children who got the shot were nine times more likely to suffer from narcolepsy, which causes a person to fall asleep suddenly and unexpectedly.
WHO spokeswoman Alison Brunier told a briefing in Geneva that Pandemrix remains on the WHO's list of prequalified vaccines, and there would be no changes to WHO recommendations as a result of the Finnish study.
"This means that countries should continue vaccinating against H1N1 to immunize people at risk of severe disease ... using monovalent vaccines, including Pandemrix, if no trivalent seasonal vaccine is available," she said.
A spokesman for Britain-based Glaxo said it had been expecting the WHO statement and was itself looking into reports of links between narcolepsy and Pandemrix.
"GSK is reviewing the Finnish report and believes it would be premature to draw any conclusions," he said in a statement.
Pandemrix was designed to tackle the H1N1 pandemic flu which spread around the world in 2009 and 2010.
It is not currently being widely used, as the pandemic was declared over in August, but doctors in some countries, such as Britain, have been advised to use it if their stocks of seasonal flu vaccines run low.
The United Nations health body said an increased risk of narcolepsy had not been seen in association with the use of any other vaccines, either against flu or other diseases.
"At this stage, it does not appear that narcolepsy following vaccination against pandemic influenza is a general worldwide phenomenon and this complicates interpretation of the findings in Finland," the WHO's advisory panel said in a statement.
It said the Stockholm-based European Center for Disease Prevention and Control (ECDC), which monitors disease in the European Union, is currently conducting studies of narcolepsy and pandemic flu vaccines.
"The findings from these studies and others, including further investigations in Finland, may help clarify the determinants of any increased risk," it said.
A WHO advisory panel made the decision after a Finnish study published last week suggested children who got the shot were nine times more likely to suffer from narcolepsy, which causes a person to fall asleep suddenly and unexpectedly.
WHO spokeswoman Alison Brunier told a briefing in Geneva that Pandemrix remains on the WHO's list of prequalified vaccines, and there would be no changes to WHO recommendations as a result of the Finnish study.
"This means that countries should continue vaccinating against H1N1 to immunize people at risk of severe disease ... using monovalent vaccines, including Pandemrix, if no trivalent seasonal vaccine is available," she said.
A spokesman for Britain-based Glaxo said it had been expecting the WHO statement and was itself looking into reports of links between narcolepsy and Pandemrix.
"GSK is reviewing the Finnish report and believes it would be premature to draw any conclusions," he said in a statement.
Pandemrix was designed to tackle the H1N1 pandemic flu which spread around the world in 2009 and 2010.
It is not currently being widely used, as the pandemic was declared over in August, but doctors in some countries, such as Britain, have been advised to use it if their stocks of seasonal flu vaccines run low.
The United Nations health body said an increased risk of narcolepsy had not been seen in association with the use of any other vaccines, either against flu or other diseases.
"At this stage, it does not appear that narcolepsy following vaccination against pandemic influenza is a general worldwide phenomenon and this complicates interpretation of the findings in Finland," the WHO's advisory panel said in a statement.
It said the Stockholm-based European Center for Disease Prevention and Control (ECDC), which monitors disease in the European Union, is currently conducting studies of narcolepsy and pandemic flu vaccines.
"The findings from these studies and others, including further investigations in Finland, may help clarify the determinants of any increased risk," it said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
